Sientra (NASDAQ:SIEN) had its target price reduced by Canaccord Genuity from $19.00 to $18.00 in a research note issued on Wednesday. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. Canaccord Genuity’s price objective indicates a potential upside of 83.67% from the stock’s previous close.
SIEN has been the subject of several other reports. BidaskClub raised shares of Sientra from a “sell” rating to a “hold” rating in a report on Friday, December 15th. Zacks Investment Research raised shares of Sientra from a “sell” rating to a “hold” rating in a report on Tuesday, January 2nd. ValuEngine lowered shares of Sientra from a “hold” rating to a “sell” rating in a report on Thursday, February 22nd. William Blair reissued a “buy” rating on shares of Sientra in a report on Thursday, March 1st. Finally, Lake Street Capital lowered shares of Sientra from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $15.00 to $11.00 in a report on Wednesday, February 21st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. Sientra presently has an average rating of “Hold” and an average price target of $13.75.
Sientra (SIEN) traded down $0.23 during trading on Wednesday, reaching $9.80. 147,200 shares of the company traded hands, compared to its average volume of 327,106. Sientra has a 12-month low of $7.20 and a 12-month high of $16.68. The stock has a market cap of $201.39, a P/E ratio of -3.37 and a beta of -1.10. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.87 and a quick ratio of 1.92.
Hedge funds have recently made changes to their positions in the business. Creative Planning boosted its holdings in shares of Sientra by 81.8% in the 4th quarter. Creative Planning now owns 47,728 shares of the medical instruments supplier’s stock valued at $671,000 after buying an additional 21,478 shares during the period. X Square Capital LLC acquired a new position in shares of Sientra in the 4th quarter valued at about $2,232,000. Pura Vida Investments LLC acquired a new position in shares of Sientra in the 3rd quarter valued at about $2,892,000. EAM Investors LLC acquired a new position in shares of Sientra in the 3rd quarter valued at about $3,018,000. Finally, Northern Trust Corp boosted its holdings in shares of Sientra by 449.4% in the 2nd quarter. Northern Trust Corp now owns 149,227 shares of the medical instruments supplier’s stock valued at $1,451,000 after buying an additional 122,066 shares during the period. 78.33% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/03/14/sientra-sien-price-target-cut-to-18-00-by-analysts-at-canaccord-genuity.html.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.